Lighter radiation, with or without hormone suppression
Part of Cancer, Kidney & urinary clinical trials.
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy, diagnosed within the last 365 days
- Your cancer is “intermediate risk” based on factors like Gleason 7, PSA 10–20, or a tumor stage T2b–T2c
- Your scans show no spread to lymph nodes or distant sites (T1–T2c, N0, M0)
- Your PSA is 20 or less within 90 days of starting, and your biopsy includes a Gleason score from the samples
- You are 18 or older and can start treatment within 56 days of joining the study
- If you’re considered for brachytherapy (internal radiation), your prostate size and urinary symptoms must meet specific limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This Phase 2 study compares two schedules of radiation treatment after prostate surgery in men whose PSA starts rising again. It aims to see which radiation approach works well while tracking quality of life and safety.
This study compares two ways of giving radiation to the prostate, including a “boost” using a special internal radiation treatment. It’s meant to see which radiation schedule works better and is safer for certain prostate cancer patients.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.